Semler Scientific Launches CardioVanta for Cardiac Disease Detection

Semler Scientific has launched CardioVanta, a new subsidiary dedicated to the early detection of cardiac diseases. This move is part of the company's broader strategy to capitalize on two high-growth areas: digital health and decentralized finance. With heart failure affecting over 6 million Americans, CardioVanta will employ a high-margin SaaS model for arrhythmia monitoring and cardiac diagnostics. Simultaneously, Semler will continue to invest in Bitcoin as a treasury reserve, aligning financial autonomy with life-saving technology to create long-term value for shareholders.

CardioVanta is set to focus on software-based tools for detecting heart failure and arrhythmias. The subsidiary will seek external capital to establish an independent valuation and fund scalable growth. The SaaS model is expected to generate recurring revenue with reduced capital intensity, supporting the company's strategy of predictable income and strategic investment. The cardiac monitoring market is expanding rapidly due to factors such as rising cardiovascular disease, increased adoption of remote devices, AI-driven analytics, and an aging population. Industry reports suggest this segment could exceed $20 billion globally by 2030. Semler’s strategy merges long-term healthcare needs with the decentralization ethos of Bitcoin, continuing to generate revenue through its established QuantaFlo platform, which supports early detection of peripheral artery disease.

Semler Scientific views its CardioVanta healthcare and Bitcoin strategy as more than just business diversification. According to CEO Doug Murphy-Chutorian, Bitcoin reflects core medical values: sustainability, transparency, and autonomy. This alignment is foundational to their mission of delivering preventative care while enabling financial freedom. The company believes this dual-focus approach appeals to investors seeking resilience across both economic and clinical environments. Semler remains the second U.S. public company to use Bitcoin as its primary reserve asset, continuing to accumulate BTC using operational cash flow and capital raises. The healthcare division reinforces this forward-looking strategy through tech-driven solutions that improve care outcomes.

By spinning off CardioVanta, Semler Scientific enables focused capital raising and valuation clarity. The CardioVanta healthcare and Bitcoin strategy supports dual monetization streams, established PAD testing, and emerging cardiac SaaS solutions. With outside investment, CardioVanta can scale without diluting existing shareholders. At the same time, Semler’s core operation remains stable, backed by FDA-cleared devices and a growing revenue base. The company’s strategy enhances flexibility to respond to evolving medical and financial landscapes. It also opens a pathway for CardioVanta to potentially list independently or attract strategic partnerships. The healthcare unit’s performance could be a future growth driver distinct from, yet complementary to, Bitcoin holdings.

Semler plans to accelerate development at CardioVanta while continuing its BTC-focused treasury operations. The CardioVanta healthcare and Bitcoin strategy will guide resource allocation, investor outreach, and innovation milestones. This model targets predictable income from SaaS and asymmetric upside from crypto. As both verticals mature, Semler aims to deliver impact through technology and autonomy, setting a new template for dual-sector innovation.